Panacea Biotec is a global generic and specialty pharmaceutical and vaccine maker registered in India with principal offices in New Delhi, Mumbai, and Lalru. Panacea Drugs Pvt. Ltd. was set up in the year 1984 and got listed in 1995 as Panacea Biotec Ltd. The company has grown organically to become one of the largest vaccine manufacturers in India. It has strong roots in research, development, manufacturing and marketing of pharmaceutical formulations, vaccines, biosimilars, and natural products. It is one of the three largest biotechnology companies in India. The company develops and produces medicines for a wide range of medical disciplines, including oncology, organ transplant,immunology and pain management, gastroenterology, vaccines, and diabetology/endocrinology. In August 2011, several of its hepatitis vaccines were removed from the list of prequalified vaccines by the World Health Organization because of quality management issues, but the issues were resolved by early 2012. Its leading product, EasyFive-TT, regained WHO PQ in September 2013.
History
Panacea Biotec is one of the largest vaccine manufacturers and pharmaceutical companies in India. Panacea Biotec is focused on research in Vaccines, Pharmaceuticals, Biosimilars, and Nutraceuticals.
Panacea Biotec has a focused presence in nephrology therapy in the highly specialized organ transplantation and dialysis management segments. It offers a range of pre-transplant and post-transplant therapies that include drugs such as lanthanum carbonate, sevelamer, and valganciclovir in conventional and novel drug delivery systems.
Gastroenterology and orthopaedic
Panacea Biotec has many products for treatment of arthritis, haemorrhoids, acid reflux, and other gastrointestinal problems. Its most prominent product is Sitcom, a euphorbia prostata extract that helps different grades of haemorrhoids. It also markets a once-a-day combination of regular and controlled-release Aceclofenac under the brand name Willgo CR.
The company has extensively focused on its diabetic portfolio with formulations such as Glicazide, Metformin, Glimepride, etc. that are marketed in India and other developing markets under the brand names Glizid, Glizid M, Glizid MR, Betaglim, Metlong, etc. It is one of the largest diabetic companies in its represented market.
Vaccines
Panacea Biotec markets many generic and novel vaccines in India and many global markets. Some of its vaccines are Pre-qualified by the WHO. The listing below is for named vaccines; Panacea Biotec produces many vaccines which do not bear trade names.
As of July 2020, the company is also developing a vaccine for SARS-COV-2 using a Whole inactivated Virus approach.
Notable achievements
In 1998, Panacea Biotec was awarded its first product patent for .
In 2005, Panacea Biotec was the first to launch a fully-liquid Pentavalent vaccine, EasyFive in India and it was subsequently, pre-qualified by the WHO for introduction in various GAVI countries.
In 2006, collaboration with the Netherlands Vaccine Institute for manufacture and marketing of a finished inactivated polio Vaccine and a number of IPV-based combination vaccines in India and across the globe
In 2008, WHO prequalification for fully liquid innovative combination pentavalent vaccine, EasyFive against five deadly infectious diseases of early childhood
In 2011, Panacea Biotec was the first to launch PacliAll, the world's first generic to Abraxane Protein-bound paclitaxel in India.
In 2017, Panacea Biotec was the first to launch a fully-liquid Hexavalent vaccine, EasySix in India.
